These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 8891470)

  • 1. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Wiseman LR; Markham A
    Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
    Shimada Y; Rougier P; Pitot H
    Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
    J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
    Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
    J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
    García-Girón C; García Palomo A; Alonso López C; León Carbonero A; Méndez Ureña M; Adróver Cebrián E; Barceló Galíndez R; Arroyo Yustos M; Alvarez Gallego J
    Clin Transl Oncol; 2005 Jul; 7(6):244-9. PubMed ID: 16131447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
    Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
    Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CPT-11 in gastrointestinal cancer.
    Bleiberg H
    Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
    Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.